Odimma is a French biotech company with a unique approach in active personalized cancer immunotherapy. Odimma believes in the future of precision medicine, and leverages recent advances in the field of immuno-oncology to fight the most hard-to-treat cancers. By harnessing the ability of the patient’s own immune system to specifically recognize non-self-targets displayed by the tumor, also called neoantigens, Odimma has designed a potent next-generation personalized immunization platform.
Immeuble le Pythagore
1 rue Jean Sapidus
Targeted indications : breast cancer, lung cancer, colorectal cancer, prostate cancer, stomach cancer, supportive care, liver cancer, brain cancer, head & neck cancer, gastrointestinal cancer, gynecological cancer, bone cancer, genitourinary cancer, skin cancer, hematologic cancer, lymphoma, myeloma, leukemia, predictive toxicology.